Source comparison
Research Peptides for Stress Fracture: BPC-157 vs TB-500 Comparison
Primary Mechanism VEGF/FGF upregulation. Drives angiogenesis and osteoblast recruitment Actin binding. Promotes cell migration, reduces inflammation Dual-pathway: angiogenic + cytoskeletal modulation Animal models only; no Phase III human trials for either pep
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF/FGF upregulation. Drives angiogenesis and osteoblast recruitment
- Actin binding. Promotes cell migration, reduces inflammation
- Dual-pathway: angiogenic + cytoskeletal modulation
- Animal models only; no Phase III human trials for either peptide
- BPC-157 targets bone-specific growth factors; TB-500 addresses systemic inflammation. Neither replaces conventional fracture care
- Optimal Timing
- Days 5–21 (soft callus phase) when angiogenesis is critical
- Days 1–7 (inflammatory phase) to reduce fibrosis and cytokine burden
- Overlapping administration across both phases
- Timing inferred from mechanism, not head-to-head trials
- Early TB-500 + mid-stage BPC-157 follows physiological healing stages
- Administration Route
- Subcutaneous near fracture site
- Subcutaneous systemic (abdomen acceptable)
- Sequential or concurrent. Both SC administration
- Site-specific vs systemic distribution differs by peptide
- Localized BPC-157; systemic TB-500. Both valid approaches
- Typical Research Dose Range
- 200–400 mcg daily (human BSA-adjusted equivalent)
- 750 mcg–1.5 mg loading twice weekly, then weekly maintenance
- BPC-157 daily + TB-500 weekly after initial loading
- Dosing extrapolated from animal models using BSA conversion
- No standardized human therapeutic dose exists for either. Research use only
- Evidence Base
- 15+ published animal studies on bone healing; zero human RCTs
- 8+ musculoskeletal animal studies; case reports only for human use
- 3 combination studies in animal models
- All evidence is preclinical. Regulatory status prohibits human therapeutic trials
- Promising preclinical data does not equal clinical proof. No FDA approval pathway
- Legal Status
- Legal to purchase for research; not approved for human therapeutic use
- Same regulatory constraints apply to combination protocols
- Both peptides exist in regulatory gray zone
- Purchasing for personal use ≠ FDA approval; no prescriber oversight for research compounds